ProfileGDS5678 / 1429063_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 74% 75% 76% 77% 74% 67% 75% 74% 74% 77% 75% 74% 74% 74% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.8716574
GSM967853U87-EV human glioblastoma xenograft - Control 24.9403775
GSM967854U87-EV human glioblastoma xenograft - Control 35.1102376
GSM967855U87-EV human glioblastoma xenograft - Control 45.3941177
GSM967856U87-EV human glioblastoma xenograft - Control 54.8099574
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.1063367
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.853775
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.8292774
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.7836474
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.2674677
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.906475
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.8341774
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.7642274
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.7825174